Pharma Commercial Launch Strategy: Practitioner Playbook

Launch execution is where pharma value is won or lost. A differentiated molecule with a weak commercial plan loses market share it never gets back. This hub covers the strategic and operational dimensions of launch that most trade publications skip — not the press release, but the playbook behind it.

Launch Risk Management

Every launch carries category-specific risk. The question isn’t whether you’ll face a launch setback, but whether your commercial infrastructure can absorb one. The posts below examine real launch challenges and what they signal for teams building their own risk frameworks.

• Safeguarding Success: How to Minimize Risks in Your Launch Strategy
• Sarepta Therapeutics in Crisis: Patient Deaths and the Safety Calculus for Gene Therapy Launches
• The Sarepta Crisis: A Watershed for Biotech Transparency, Governance, and Trust
• Sarepta Therapeutics Faces Increased Scrutiny: What It Means for LGMD Research

Go-to-Market Execution

Formulary access, payer contracting, and channel strategy are the operational levers that determine whether a launch takes hold. These posts examine real-world commercial execution across asset types and therapy areas.

• FluoGuide Q1 2024: Commercial Lessons for Targeted Urology Launches
• Biohaven’s Vyglxia Launch Strategy for Spinocerebellar Ataxia
• Repatha’s Market Strategy: What a 25% Outcomes Reduction Gets You in Access
• Gilead’s ‘Living Beyond MBC’: Patient Support as a Commercial Strategy
• Novartis Launches Malaria Treatment for Infants: Access Strategy in Low-Income Markets

LOE Strategy and Portfolio Defense

Loss of exclusivity is a commercial event as much as a patent event. How teams prepare — through lifecycle extensions, biosimilar contracting strategy, or portfolio transition — determines how much revenue survives the cliff.

• Merck’s $3 Billion Budget Shift: Preparing for Keytruda’s Post-Exclusivity Era
• CMS Launches the GENEROUS Model: What It Means for Medicaid-Dependent Franchises
• Three Launches, Three Strategies: Madrigal, Apellis, and PTC in One Week

Commercial Infrastructure and Capabilities

Building the field, the hub, and the digital layer — and knowing which one to prioritize when you can’t afford all three on launch day. M2M covers the capability-building challenges that define modern pharma commercial organizations.

• The State of HCP Engagement 2026: Data vs. Hype Report
• Opinion: Biopharma’s Role in Preparing for the Next Pandemic
• Pfizer vs. Novo: Commercial Positioning in a Crowded Weight-Loss Market

For related coverage on payer strategy and formulary access, see our Drug Pricing & Market Access Hub.